Company Analysis Protagenic Therapeutics Inc
1. Summary
Advantages
- The stock's return over the last year (476.92%) is higher than the sector average (19.44%).
- Current debt level 0% is below 100% and has decreased over 5 years from 156.25%.
Disadvantages
- Price (0.01 $) is higher than fair price (0.0081 $)
- Dividends (0%) are below the sector average (0%).
- The company's current efficiency (ROE=-236.06%) is lower than the sector average (ROE=385.88%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Protagenic Therapeutics Inc | Index | ||
|---|---|---|---|
| 7 days | 50% | -0.6% | 0.6% |
| 90 days | 194.1% | -3.1% | 0.2% |
| 1 year | 476.9% | 19.4% | 18.1% |
PTIXW vs Sector: Protagenic Therapeutics Inc has outperformed the "" sector by 457.49% over the past year.
PTIXW vs Market: Protagenic Therapeutics Inc has outperformed the market by 458.86% over the past year.
Slightly volatile price: PTIXW is more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical deviations of about +/- 5-15% per week.
Long period: PTIXW with weekly volatility of 9.17% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Above fair price: The current price (0.01 $) is higher than the fair price (0.0081 $).
Price is higher than fair: The current price (0.01 $) is 19% higher than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (-0.0255) is lower than that of the sector as a whole (37.13).
P/E vs Market: The company's P/E (-0.0255) is higher than that of the market as a whole (-99.49).
5.3. P/BV
P/BV vs Sector: The company's P/BV (0.0218) is higher than that of the sector as a whole (-2038.83).
P/BV vs Market: The company's P/BV (0.0218) is lower than that of the market as a whole (71.88).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (0) is lower than that of the sector as a whole (28.06).
P/S vs Market: The company's P/S indicator (0) is lower than that of the market as a whole (113.77).
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (0.33) is higher than that of the sector as a whole (-870.14).
EV/Ebitda vs Market: The company's EV/Ebitda (0.33) is higher than that of the market as a whole (-78.41).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Rising and has grown by 2.16% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (2.16%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-59.39%).
6.4. ROE
ROE vs Sector: The company's ROE (-236.06%) is lower than that of the sector as a whole (385.88%).
ROE vs Market: The company's ROE (-236.06%) is lower than that of the market as a whole (-6.24%).
6.6. ROA
ROA vs Sector: The company's ROA (-175.99%) is lower than that of the sector as a whole (-51.45%).
ROA vs Market: The company's ROA (-175.99%) is lower than that of the market as a whole (38.46%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (9.59%).
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
Based on sources: porti.ru
